Knight Therapeutics Inc (KHTRF) Q1 2025 Earnings Call Highlights: Strategic Expansions and ...

GuruFocus News

Fri, May 9, 2025, 12:19 AM 3 min read

Release Date: May 08, 2025

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

• Knight Therapeutics Inc (KHTRF) launched Minjuvi successful Mexico and ONE successful Brazil and Mexico, expanding their marketplace presence.

• Revenues accrued by $2 cardinal oregon 3% compared to Q1 past year, with a changeless currency maturation of 8%.

• The oncology and hematology portfolio grew by 6% connected a changeless currency basis, driven by cardinal promoted brands.

• The institution signed a 3rd declaration with the Ministry of Health successful Brazil, expecting to present $22.4 cardinal successful 2025.

• Knight Therapeutics Inc (KHTRF) closed a $40 cardinal moving superior enactment of recognition from Citibank, enhancing fiscal flexibility.

• The infectious illness portfolio saw a gross alteration of $2 cardinal oregon 4%.

• Registered EBITDA decreased by $1.5 cardinal oregon 11% compared to the aforesaid play past year.

• Operating expenses accrued by $3 cardinal oregon 10%, driven by commercialized walk and transaction fees.

• The institution recorded a nett nonaccomplishment of $3.8 cardinal connected fiscal assets owed to marketplace revaluation.

• Inventory accrued by $37 million, impacting currency travel owed to timing of orders and deliveries.

• Warning! GuruFocus has detected 6 Warning Sign with KHTRF.

Q: How should we deliberation astir SG&A levels going forward, particularly with the Palatin acquisition expected mid-year? A: Unidentified_1: We don't supply guidance connected OpEx, but our gross and IIA borderline guidance includes the Palatin acquisition. We expect to extremity the twelvemonth with $390 to $405 cardinal successful apical enactment and an IIA borderline of 13%. OpEx volition set to present these results.

Q: Can you supply updates connected the Palatin acquisition process and immoderate closing details? A: Unidentified_1: We don't person much details beyond the mid-year timeline. Regulatory and modular consents required for the transaction are progressing arsenic planned, and we expect to conscionable our forecasted timelines.

Q: Could you remark connected the emblematic seasonality crossed your jurisdictions and its interaction connected your business? A: Unidentified_1: Canada experiences mean seasonality with Q4 usually being larger owed to wholesaler buying patterns. Brazil besides has immoderate seasonality, impacting our concern much owed to its size. Other markets are comparatively even, but with Palatin, we expect much seasonality successful our business.

Q: What are the fiscal results for Q1 2025, and however bash they comparison to past year? A: Unidentified_2: For Q1 2025, we delivered revenues of $88 million, a 3% summation from past year. On a changeless currency basis, revenues accrued by 8%. Our oncology and hematology portfolio grew by 6%, portion the infectious illness portfolio grew by 3% connected a changeless currency basis.